11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Avidity Biosciences Inc. (RNA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 7,500,000 | $218,100,000 | +10% | 3.08% |
| 2. | RA Capital Management Peter Kolchinsky | 6,300,408 | $183,215,865 | 2.43% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 2,751,944 | $80,026,532 | -11% | 0.13% |
| 4. | Casdin Capital Eli Casdin | 2,045,000 | $59,468,600 | -2% | 3.95% |
| 5. | Boxer Capital Aaron Davis And Christopher Fuglesang | 1,727,388 | $50,232,443 | 4.27% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 800,000 | Large Shareholder | 4,795,000 | 2021-08-04 | Filing | |
| $18.00 | 300,000 | Other | 2,514,545 | 2020-06-16 | Filing | |
| $18.00 | 950,000 | Large Shareholder | 3,995,000 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.06 | 9,578 | Officer | 72,850 | 2025-03-20 | Filing | |
| $31.06 | 31,540 | Officer, Director | 305,871 | 2025-03-20 | Filing | |
| $31.06 | 11,780 | Officer | 80,195 | 2025-03-20 | Filing | |
| $31.06 | 7,935 | Officer | 96,720 | 2025-03-20 | Filing | |
| $31.06 | 7,778 | Officer | 97,130 | 2025-03-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,509,606 | $480,099,340 | 0.02% | |
| 2. | 9,932,366 | $288,833,205 | 0% | |
| 3. | 9,431,911 | $274,279,972 | 0% | |
| 4. | 8,106,097 | $235,725,302 | 0.04% | |
| 5. | 7,932,870 | $230,687,860 | 3.48% |
News See All
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
12 Best Multibagger Stocks to Buy Right Now
The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs.
7 Best Performing Long Term Stocks in 2024
After the latest 50 basis point rate cut by the Federal Reserve, the market has been performing well.
10 Best Performing Small-Cap Stocks in 2024
The recent Fed rate cut has made the market cautiously optimistic. Despite the unusual timing, historical data suggests a continued upward trend. Recently, we discussed the Dow's new all-time high.
5 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at five cheap small cap stocks to buy before the next breakout.
Is RNA A Good Stock To Buy According To Hedge Funds?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September...
BioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management
Jacob Gottlieb's Visium Asset Management has recently revealed its equity positions as of the end of the fourth quarter in a 13F filing with the Securities and Exchange Commission.
James Flynn, Deerfield Buy RNA-Themed Prosensa
James Flynn, Deerfield: Prosensa Holding NV (NASDAQ:RNA) recently became an addition in the equity portfolio of Deerfield Management, managed by James E. Flynn.